Fragen und Antworten zur COVID-19-Impfung

1. Impfstoffe gegen COVID-19: Liste der klinischen Versuche (infovac.ch),

2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants - Full Text View - ClinicalTrials.gov

3. https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Vierte_Empfehlung_2021-04-01.html

4. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/05_21.pdf?__blob=publicationFile

5. Lopez Bernal J, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. Verfügbar als Preprint vom 2 März 2021. Online verfügbar unter https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1

6. Vasileiou E, Simpson CR, Robertson C, Shi T, Kerr S, Agrawal U, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. 2021. Verfügbar als Preprint vom 19. Februar 2021. Online verfügbar unter: SSRN: https://ssrn.com/abstract=3789264

7. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/12_21.pdf?__blob=publicationFile

8. Paul-Ehrlich-Institut - Meldungen - Das Paul-Ehrlich-Institut informiert – Vorübergehende Aussetzung der Impfung mit dem COVID-19-Impfstoff AstraZeneca (pei.de)

9. https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/AstraZeneca-Impfstoff-2021-03-19.html

10. 21-03-23-covid-19-vaccine-astrazeneca.pdf (pei.de)

11. RKI - Impfen - Fragen zur COVID-19-Impfempfehlung (Stand 1.4.2021)

12. Pinschewer DD. Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. Swiss Med Wkly. 2017 Aug 8;147:w14465. doi: 10.4414/smw.2017.14465.

13. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. 

14. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 Jan 13:NEJMoa2034201. doi: 10.1056/NEJMoa2034201. Epub ahead of print.

15. Salisch NC, Stephenson KE, Williams K, et al. A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. Ann Intern Med. 2021 Feb 16. doi: 10.7326/M20-5306. Epub ahead of print.

16. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615.

17. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Kehtan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416.

18. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/12_21.pdf?__blob=publicationFile

19. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020 May 19;52(5):737-741.

20. Pfizer/BioNTech say data suggests vaccine 94% effective in preventing asymptomatic infection | Reuters

21. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Apr 15;384(15):1412-1423

22. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/12_21.pdf?__blob=publicationFile

23. Rasmussen SA, Jamieson DJ. Pregnancy, Postpartum Care, and COVID-19 Vaccination in 2021. JAMA. 2021 Feb 8. doi: 10.1001/jama.2021.1683. Epub ahead of print

24. Davanzo R, Agosti M, Cetin I, Chiantera A, Corsello G, Ramenghi LA, Staiano A, Tavio M, Villani A, Viora E, Mosca F. Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies. Ital J Pediatr. 2021 Feb 27;47(1):45

25. Betreff (pei.de),

26. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 | MMWR (cdc.gov)

27. Liu MA. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019 Apr 24;7(2):37. doi: 10.3390/vaccines7020037

28. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-bis-02-04-21.pdf?__blob=publicationFile&v=4    

29. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/12_21.pdf?__blob=publicationFile

30. https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/AstraZeneca-Impfstoff-2021-03-19.html

31. CoronaImpfV_BAnz_AT_08.02.2021_V1.pdf (bundesgesundheitsministerium.de)

32. RKI - Empfehlungen der STIKO - Stellungnahme der Ständigen Impfkommission zum Zeitpunkt der Gabe eines mRNA-Impfstoffs nach Erstimpfung mit AstraZeneca Vaccine (Vaxzevria) bei <60-Jährigen

33. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881-891.

34. https://comcovstudy.org.uk/about-com-cov2

35. No evidence Pfizer Covid-19 vaccine affects women’s fertility - Full Fact

36. https://clinicaltrials.gov/ct2/show/NCT04796896?cond=Covid19+vaccine&age=0&draw=3&rank=14

37. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

38. Moderna says protection from its COVID-19 vaccine still strong six months on | Reuters

39. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, Marquez PL, Olson CK, Liu R, Chang KT, Ellington SR, Burkel VK, Smoots AN, Green CJ, Licata C, Zhang BC, Alimchandani M, Mba-Jonas A, Martin SW, Gee JM, Meaney-Delman DM; CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2104983. Epub ahead of print. PMID: 33882218.

40. Harder T, Koch J, Vygen-Bonnet S, Scholz S, Pilic A, Reda S, Wichmann O: Wie gut schützt die COVID-19-Impfung vor SARS-CoV-2-Infektionen und SARS-CoV-2-Transmission? – Systematischer Review und Evidenzsynthese Epid Bull 2021;19:13-23 | DOI 10.25646/8442 (online vorab am 6. Mai 2021 erschienen)

41. RKI - Archiv 2021 - Beschluss der STIKO zur 5. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung

42. SIKO rät zu COVID-Impfung bei Schwangeren (aerztezeitung.de) 12.5.2021

43. Pfizer und BioNTech starten globale klinische Studie zur Untersuchung des COVID-19-Impfstoffs in schwangeren Frauen

44. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063. doi: 10.1126/science.abf4063. Epub 2021 Jan 6

45. El uso combinado de las vacunas de AstraZeneca y Pfizer contra el SARS-CoV-2 ofrece una potente respuesta inmunitaria (isciii.es)

46. Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. Published online May 13, 2021. doi:10.1001/jama.2021.7563

47. https://www.fda.gov/media/148542/download

48. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: Lancet. 2020 Aug 15;396(10249):466. Erratum in: Lancet. 2020 Dec 12;396(10266):1884. PMID: 32702298; PMCID: PMC7445431.

49. Vaccines highly effective against B.1.617.2 variant after 2 doses - GOV.UK (www.gov.uk)

50. Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Pfizer, New York, April 1, 2021 (Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study | pfpfizeruscom ) (press release).

51. Doria-Rose N, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Jun 10;384(23):2259-2261.

52. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study (medrxiv.org)

53. Vygen-Bonnet S, Koch J, Berner R, Bogdan C, Harder T, Heininger U, Hummers E, Littmann M, Meerpohl J, Mertens T, Meyer H, Neufeind J, Schmid-Küpke N, Scholz S, Terhardt M, Überla K, van der Sande M, Waize M, Wichmann O, Wicker S, Widders G, Wiedermann U, Wild V, Zepp F, von Kries R: Beschluss der STIKO zur 6. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Epid Bull 2021;23:3 -32 | DOI 10.25646/8596

54. BAnz AT 02.06.2021 V2.pdf (bundesanzeiger.de)

55. CureVac gibt Status-Update zur Phase 2b/3-Studie für Impfstoffkandidat der ersten Generation CVnCoV bekannt - CureVac

56. Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

57. Frenck RW Jr, rt al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021;385(3):239-250

58. Vygen-Bonnet S, Koch J, Bogdan C, Heininger U, Littmann M, Meerpohl J, Meyer H, Mertens T, Michaelis K, Terhardt M, Überla K, van der Sande M, Wichmann O, Wicker S, Wiedermann U, Wild V, von Kries R: Beschluss der STIKO zur 8. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Epid Bull 2021;27:14–31 | DOI 10.25646/8776

59. Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021 Jun 26;397(10293):2461-2462.

60. Schiffner J, Backhaus I, Rimmele J, Schulz S, Möh­lenkamp T, Klemens JM, et al. Long-term course of humoral and cellular immune responses in outpatients after SARS-CoV-2 infection. Preprint vom 25. Juni 2021 verfügbar unter: www.medrxiv.org/ content/10.1101/2021.06.24.21259218v1

61. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).

62. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. The Lancet. 2021;397(10289):2043-6.

63. Liu X, Shaw RH, Stuart AS, Greenland M, Dinesh T, Snape MDea. Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Rando­mised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine. Verfügbar unter: dx.doi.org/10.2139/ssrn.3874014. 2021.

64. Borobia AM, Carcas AJ, Pérez Olmeda MT, Castaño L, Jesús Bertrán M, García-Pérez J, et al. Reactoge­nicity and Immunogenicity of BNT162b2 in Sub­jects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS). Verfügbar unter: https://papers. ssrn.com/sol3/papers.cfm?abstract_id=3854768. 2021.

65. Wichmann O, Scholz S, Waize M, Schmid-Küpke N, Hamouda O, Wieler LH, Schaade L: Welche Impfquote ist notwendig, um COVID-19 zu kontrollieren? Epid Bull 2021;27:3-13 | DOI 10.25646/8742

66.   H Feng et al., https://www.medrxiv.org/content/10.1101/2021.06.21.21258528v1

67. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 May 17. doi: 10.1038/s41591-021-01377-8. Epub ahead of print.

68. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-bis-31-05-21.pdf?__blob=publicationFile&v=8

69.  Thompson MG, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jun 30:NEJMoa2107058. doi: 10.1056/NEJMoa2107058. Epub ahead of print.

70.  Ethikratvorsitzende zu Impfpflicht: „Wir brauchen das gar nicht“ (aerztezeitung.de) Aerztezeitung vom 13.7.2021

71.  Paul-Ehrlich-Institut - Coronavirus und COVID-19 - Sicherheit von COVID-19-Impfstoffen (pei.de)

72. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM

73. SARS-CoV-2 variants of concern as of 15 July 2021 (europa.eu)

74. Delta Variant Spread Seen Pushing Covid Herd Immunity Threshold Above 80% - Bloomberg

75. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N, Foreman A, Schubert PL, Gallagher GR, Fink T, Madoff LC, Gabriel SB, MacInnis B, Park DJ, Siddle KJ, Harik V, Arvidson D, Brock-Fisher T, Dunn M, Kearns A, Laney AS. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-1062.

76. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021. MMWR Morb Mortal Wkly Rep. ePub: 6 August 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7032e1

77. A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to < 18 Years Old to Prevent COVID-19 - Full Text View - ClinicalTrials.gov

78. A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 Against COVID-19 in Healthy Participants - Full Text View - ClinicalTrials.gov

79. Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, Ding B, Dooley J, Girard B, Hillebrand W, Pajon R, Miller JM, Leav B, McPhee R. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMoa2109522. Epub ahead of print. PMID: 34379915.

80. Pfizer and BioNTech Press Ahead on Booster Shots - The New York Times (nytimes.com)

81. J&J says booster dose increased antibodies in early-stage trials | Reuters

82. Vygen-Bonnet S, Koch J, Armann J, Berner R, Bogdan C, Harder T, Heininger U, Hummers E, Littmann M, Meerpohl J, Mertens T, Meyer H, Neufeind J, Schmid-Küpke N, Scholz S, Terhardt M, Überla K, van der Sande M, Waize M, Wichmann O, Wicker S, Widders G, Wiedermann U, Wild V, Zepp F, von Kries R: Beschluss der STIKO zur 9. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung. Epid Bull 2021;33:3-46 | DOI 10.25646/8942

83 .https://www.dgkj.de/fileadmin/user_upload/Meldungen_2021/210617_CoronaTaskForce_Schutzimpfung_aktualisiert.pdf (zugegriffen am 3.9.2021)

84. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI, Gabrovska N, Velizarova S, Prunk P, Osterman V, Krivec U, Lo Vecchio A, Shingadia D, Soriano-Arandes A, Melendo S, Lanari M, Pierantoni L, Wagner N, L'Huillier AG, Heininger U, Ritz N, Bandi S, Krajcar N, Roglić S, Santos M, Christiaens C, Creuven M, Buonsenso D, Welch SB, Bogyi M, Brinkmann F, Tebruegge M; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020;4(9):653-661

85. Risk factors for hospitalization, disease severity and mortality in children and adolescents with COVID-19: Results from a nationwide German registry | medRxiv (zugegriffen am 3.9.2021)

86.  Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, Amanat F, Rauseo AM, Haile A, Xie X, Klebert MK, Suessen T, Middleton WD, Shi PY, Krammer F, Teefey SA, Diamond MS, Presti RM, Ellebedy AH. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021 Aug;596(7870):109-113.

87.  Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, Petersen EE, Ju J, Beauregard J, Wilcox AJ, Rose CE, Meaney-Delman DM, Ellington SR; CDC v-safe Covid-19 Pregnancy Registry Team. Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion. N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMc2113891. Epub ahead of print. 

88. Kharbanda EO, Haapala J, DeSilva M, Vazquez-Benitez G, Vesco KK, Naleway AL, Lipkind HS. Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy. JAMA. 2021 Sep 8. doi: 10.1001/jama.2021.15494. Epub ahead of print.

89.  Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America by Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana, Gustavo Jose Aroca Martinez, Marc J.M. Bonten, Reynaldo Chandler, Gonzalo Corral, Eddie Jan Louis De Block, Lucie Ecker, Julian Justin Gabor, Carlos Alberto Garcia Lopez, Lucy Gonzales, María Angélica Granados González, Nestor Gorini, Martin P. Grobusch, Adrian D. Hrabar, Helga Junker, Alan Kimura, Claudio F. Lanata, Clara Lehmann, Isabel Leroux-Roels, Philipp Mann, Michel Fernando Martinez-Reséndez, Theresa Ochoa, Carlos Alberto Poy, Maria Jose Reyes Fentanes, Luis Maria Rivera Mejia, Vida Veronica Ruiz Herrera, Xavier Sáez-Llorens, Oliver Schönborn-Kellenberger, Mirjam Schunk, Alexandra Sierra Garcia, Itziar Vergara, Thomas Verstraeten, Marisa Vico, Lidia Oostvogels, HERALD Study Group :: SSRN

90. Epidemiologisches Bulletin 38/2021 (rki.de)[BDY1] 

91. Takla A, Matysiak-Klose D, Bogdan C, Harder T, Ledig T, Neufeind J, Pecks U, Schleußner E, van der Sande M, Röbl-Mathieu M: Empfehlung und Begründung der STIKO zur Impfung gegen COVID-19 von Schwangeren und Stillenden Epid Bull 2021;38:3-29

92. Ständige Impfkommission: Beschluss der STIKO zur 11. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2021;39:3 -11

93. Falsey AR, Frenck RW Jr, Walsh EE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Bailey R, Swanson KA, Xu X, Koury K, Kalina W, Cooper D, Zou J, Xie X, Xia H, Türeci Ö, Lagkadinou E, Tompkins KR, Shi PY, Jansen KU, Şahin U, Dormitzer PR, Gruber WC. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021 Sep 15:NEJMc2113468. doi: 10.1056/NEJMc2113468

94. Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021 Sep 15:NEJMoa2110345. doi: 10.1056/NEJMoa2110345. Epub ahead of print. PMID: 34525277; PMCID: PMC8461570.

95. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, Huppert A. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021 Sep 15:NEJMoa2114255. doi: 10.1056/NEJMoa2114255.

96. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021 Mar 27;397(10280):1204-1212. doi: 10.1016/S0140-6736(21)00575-4. Epub 2021 Mar 17. PMID: 33743221; PMCID: PMC7969130

97. RKI - Coronavirus SARS-CoV-2 - Digitales Impfquotenmonitoring zur COVID-19-Impfung
Und COVID-19 Impfdashboard

98. Deutsche Aerztezeitung vom 12, Oktober 2021, https://www.aerztezeitung.de/Wirtschaft/CurVac-gibt-COVID-Impfstoffkandidaten-auf-423577.html?utm_campaign=SocialMediaShare&utm_source=Story&utm_medium=Email

99. https://www.sciencemediacentre.org/expert-comments-on-the-ay-4-2-subvariant/

100. Reis BY, Barda N, Leshchinsky M, Kepten E, Hernán MA, Lipsitch M, Dagan N, Balicer RD. Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114290. Epub ahead of print

101. Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2113864. Epub ahead of print

102. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/43_21_Auffrischimpfung.pdf?__blob=publicationFile

103. Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine | BioNTech

104. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 | MMWR (cdc.gov)

105. Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 – Valneva

106. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo R, Alroy-Preis S, Ash N, Huppert A. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2114228. Epub ahead of print. PMID: 34706170.

107. Ständige Impfkommission: Beschluss der STIKO zur 13. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2021;46:10 -19 | DOI 10.25646/9281

108. Koch J, Vygen-Bonnet S, Bogdan C, Burchard G, Garbe E, Heininger U, Hummers E, Keller-Stanislawski B, von Kries R, Ledig T, Littmann M, Meerpohl J, Mertens T, Oberle D, Röbl-Mathieu M, van der Sande M, Terhardt M, Überla K, Wichmann O, Wicker S, Wieder­mann-Schmidt U, Widders G, Zepp F: STIKO-Empfeh­lung im Alter unter 30 Jahren ausschließlich Comirnaty zur COVID-19-Grundimmunisierung und Auffrischimpfung zu verwenden und die dazugehörige wissen­schaftliche Begründung. Epid Bull 2021;46:20-32 | DOI 10.25646/9278

109. de Gier Brechje, Andeweg Stijn, Backer Jantien A, RIVM COVID-19 surveillance and epidemiology team, Hahné Susan JM, van den Hof Susan, de Melker Hester E, Knol Mirjam J. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. Euro Surveill. 2021;26(44):pii=2100977. https://doi.org/10.2807/1560-7917.ES.2021.26.44.2100977

110. Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simões EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Rämet M, Munjal I, Perez JL, Frenck RW Jr, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Türeci Ö, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;386:35-46

111. Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 | European Medicines Agency (europa.eu)

112. Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age | Moderna, Inc. (modernatx.com)

113. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 Study Group. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMoa2116185. Epub ahead of print. PMID: 34910859.

114. Artikel Druckansicht (aerztezeitung.de)

115. Koch J, Vygen-Bonnet S, Harder T, Ledig T, Mertens T, Michaelis K, Schönfeld V, Schmid-Küpke N, Steffen A, Wichmann O, Wicker S, Überla K: STIKO-Empfehlung zur COVID-19-Auffrischimpfung mit einem mRNA-Impfstoff für Personen ≥ 70 Jahre und bestimmte Indikationsgruppen sowie Empfehlung zur Optimie­rung der Grundimmunisierung mit einem mRNA-Impfstoff nach vorausgegangener Impfung mit der COVID-19 Vaccine Janssen und die dazugehörige wissenschaftliche Begründung. Epid Bull 2021;43:12 -49

116. Ständige Impfkommission: Beschluss der STIKO zur 14. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2021;48:3-14

117. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 Oct 29;398 (10316):2093–100. doi: 10.1016/S0140-6736(21)02249-2. Epub ahead of print. PMID: 34756184; PMCID: PMC8555967

118. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2115624?articleTools=true

119. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2115926?articleTools=true

120. https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2021-12-09.html

121. https://www.bmj.com/content/375/bmj-2021-067873.long

122. RKI - Impfungen A - Z - STIKO-Empfehlung zur COVID-19-Impfung

123. https://www.ahajournals.org/doi/epdf/10.1161/CIRCULATIONAHA.121.056583

124. https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu

125. RKI - Coronavirus SARS-CoV-2 - Epidemiologischer Steckbrief zu SARS-CoV-2 und COVID-19

126. Ständige Impfkommission: Beschluss der STIKO zur 16. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2022;1:3 -15 | DOI 10.25646/9437

127. Ständige Impfkommission: Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2021. Epid Bull 2021;34:3-63

128. Impf_info_A4_web.indd (dgaki.de)

129. https://www.rki.de/SharedDocs/FAQ/COVID-Impfen/Flowchart_Allergieanamnese.pdf?__blob=publicationFile

130. https://www.bundesgesundheitsministerium.de/coronavirus/faq-covid-19-impfung.html#c21990

131. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California (medrxiv.org)

132. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study | medRxiv

133. Artikel Druckansicht (aerztezeitung.de)

134. Ständige Impfkommission: Beschluss der STIKO zur 17. Aktualisierung der COVID-19-Impfempfehlung Epid Bull 2022;3:7-20

135. Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, Pannaraj PS, Irby K, Walker TC, Schwartz SP, Maddux AB, Mack EH, Bradford TT, Schuster JE, Nofziger RA, Cameron MA, Chiotos K, Cullimore ML, Gertz SJ, Levy ER, Kong M, Cvijanovich NZ, Staat MA, Kamidani S, Chatani BM, Bhumbra SS, Bline KE, Gaspers MG, Hobbs CV, Heidemann SM, Maamari M, Flori HR, Hume JR, Zinter MS, Michelson KN, Zambrano LD, Campbell AP, Patel MM, Randolph AG; Overcoming Covid-19 Investigators. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. N Engl J Med. 2022 Jan 12:NEJMoa2117995. doi: 10.1056/NEJMoa2117995. Epub ahead of print. 

136. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based

137. https://promedmail.org/

138. https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/18_Aktualisierung_Covid.pdf?__blob=publicationFile

139. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, et al. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. N Engl J Med. 2022 Apr 7;386(14):1377-1380.

140. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:264–270. DOI: http://dx.doi.org/10.15585/mmwr.mm7107e3

141. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency

142. Ständige Impfkommission: Beschluss der STIKO zur 15. Aktualisierung der COVID-19-Impfempfehlung Epid Bull 2022;1:3-15

143. EMA: Neues zu COVID-19-Impfstoffen, zu Migräne und zur Onkologie (medscape.com)

144. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant (medrxiv.org)
 

145. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022 (cdc.gov)

146. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022 | MMWR (cdc.gov)

147. mm7111e1 Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 (cdc.gov)

148. Sinovac Vaccine Is 38% Effective In Shielding Kids From Covid, Data Show - Bloomberg

149. Yamamoto S, Mizoue T, Tanaka A, Oshiro Y, Inamura N, Konishi M, Ozeki M, Miyo K, Sugiura W, Sugiyama H, Ohmagari N. Sex-associated differences between body mass index and SARS-CoV-2 antibody titers following the BNT162b2 vaccine. Obesity (Silver Spring). 2022 Feb 28. doi: 10.1002/oby.23417. Epub ahead of print. PMID: 35226399.

150. Yamamoto S, Mizoue T, Tanaka A, Oshiro Y, Inamura N, Konishi M, Ozeki M, Miyo K, Sugiura W, Sugiyama H, Ohmagari N. Sex-associated differences between body mass index and SARS-CoV-2 antibody titers following the BNT162b2 vaccine. Obesity (Silver Spring). 2022 Feb 28. doi: 10.1002/oby.23417. Epub ahead of print. PMID: 35226399.

151. Deltakron-Variante: Symptome, Entstehung, Ausbreitung in Deutschland (augsburger-allgemeine.de)

152. Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore KM, Floyd K, Foster SL, Posavad CM, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Sullivan NJ, Roberts PC, Beigel JH, Korber B, Baden LR, El Sahly H, Chalkias S, Zhou H, Feng J, Girard B, Das R, Aunins A, Edwards DK, Suthar MS, Mascola JR, Montefiori DC. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022 Mar 17;386(11):1088-1091.

153. The Concept of Classical Herd Immunity May Not Apply to COVID-19 - PubMed (nih.gov)

154. IDSA Daily News Briefing - Briefing (bulletinhealthcare.com)

155. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2202826. Epub ahead of print. PMID: 35353976.

156. Impfpflicht in Praxen: Ungeimpfte Mitarbeiter müssen nicht zwingend freigestellt werden! (aerztezeitung.de)

157. RKI - Archiv 2022 - Epidemiologisches Bulletin 13/2022

158. Hall V, et al; SIREN Study Group. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022 Mar 31;386(13):1207-1220

159. ProMed News, 6. April 2022, Home - ProMED - ProMED-mail (promedmail.org)

160. Markov, P.V., Katzourakis, A. & Stilianakis, N.I. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. Nat Rev Microbiol (2022)

161. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, Alroy-Preis S, Ash N, Huppert A, Milo R. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022 Apr 5. doi: 10.1056/NEJMoa2201570. Epub ahead of print. PMID: 35381126.

162. Mehrheit des Ethikrats für erweiterte Impfpflicht (aerztezeitung.de)

163. Artikel Druckansicht (aerztezeitung.de)

164. Moderna - Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform (modernatx.com)

165. Auster O, Finkel U, Dagan N, Barda N, Laufer A, Balicer RD, Ben-Shachar S. Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older. JAMA Netw Open. 2022 Apr 1;5(4):e227657

166. Shiraz El Adam, MSc, Macy Zou, MPH, Shinhye Kim, MSc, Bonnie Henry, MD, Mel Krajden, MD, Danuta M Skowronski, MD, SARS-CoV-2 mRNA vaccine effectiveness in healthcare workers by dosing interval and time since vaccination: test negative design, British Columbia, Canada, Open Forum Infectious Diseases, 2022;, ofac178, https://doi.org/10.1093/ofid/ofac178

167. Moderna - Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform (modernatx.com)

168. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr 21;386(16):1532-1546.

169. https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-files-us-authorization-covid-shot-kids-under-6-2022-04-28/

170. Dai L, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.

171. Hager KJ,  et al; CoVLP Study Team. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300. Epub ahead of print.

168. Ständige Impfkommission: Beschluss der STIKO zur 20. Aktualisierung der COVID-19-Impfempfehlung Epid Bull 2022;21:3-19

169. Piechotta V, Koch J, Vygen-Bonnet S, Armann J, Berner R, Bogdan C, Burchard G, Garbe E, Heininger U, Hummers E, von Kries R, Ledig T, Littmann M, Meerpohl J, Mertens T, Meyer H, , Röbl-Mathieu M, Neufeind J, van der Sande M, Schmid-Küpke N, Terhardt M, Überla K, Wichmann O, Wicker S, Wieder­mann-Schmidt U, Widders G, Wild V, Zepp F: Wissenschaftliche Begründung der STIKO zur Modifizierung der COVID-19-Impfempfehlung für Kinder im Alter von 5 – 11 Jahren , Epid Bull 2022;21:20-43

170. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr 21;386(16):1532-1546.

171. https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-files-us-authorization-covid-shot-kids-under-6-2022-04-28/

172. Hager KJ,  et al; CoVLP Study Team. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300. Epub ahead of print.

173. Dai L, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.

174. https://www.theguardian.com/commentisfree/2022/may/16/covid-19-pandemic-exit-roadmap?CMP=twt_b-usopinion_c-us

175. Carlsen EØ, Magnus MC, Oakley L, et al. Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants. JAMA Intern Med. Published online June 01, 2022. doi:10.1001/jamainternmed.2022.2442

176. Holm M, Espenhain L, Glenthøj J, Schmidt LS, Nordly SB, Hartling UB, Nygaard U. Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children Before and During the Omicron Wave. JAMA Pediatr. 2022 Jun 8:e222206. doi: 10.1001/jamapediatrics.2022.2206. Epub ahead of print.

177. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965. Epub ahead of print. PMID: 35704396.

178. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2206576. Epub ahead of print. 

179. Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, Smith ZR, Miller J, Verani JR, Schrag SJ. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA. 2022 Jun 14;327(22):2210-2219.

180. Halasa NB, Olson SM, Staat MA, et al. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. N Engl J Med. 2022;387(2):109-119. 

181. Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

182. Grünes Licht für proteinbasierten Corona-Impfstoff bei Teenagern (Ärztezeitung, 24.06.2022)

183. EU-Behörde empfiehlt Zulassung von Covid-19-Impfstoff von Valneva (Handelsblatt, 23.06.2022)

184. Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron (businesswire, 25.06.2022)

185. Chalkias S, Harper C, Vrbicky K et al. A Bivalent Omicron-containing Booster Vaccine Against Covid-19 medRxiv 2022.06.24.22276703; doi: https://doi.org/10.1101/2022.06.24.22276703 Epub ahead of print, not peer reviewed

186. Townsend JP, Hassler HB, Sah P. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2204336119. doi: 10.1073/pnas.2204336119.

187. Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N Engl J Med. 2022 Jul 21;387(3):227-236

188. Tan SHX, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. N Engl J Med. 2022 Jul 20. doi: 10.1056/NEJMoa2203209. Epub ahead of print.

189. Fleming-Dutra KE, Wallace M, Moulia DL, et al. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 1;71(26):859-868.

190. Falman A, Harder T, Wieler LH, Wichmann O: Wie gut und wie lange schützt eine SARS-CoV-2-Infektion vor einer Reinfektion? Epid Bull 2022;31:3-12

191. Houghton DE, Wysokinski W, Casanegra AI, et al. Risk of venous thromboembolism after COVID-19 vaccination. J Thromb Haemost. 2022 Jul;20(7):1638-1644.

192. Launay O, Cachanado M, Luong Nguyen LB, et al. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. N Engl J Med. 2022 Jun 29:NEJMc2206711. doi: 10.1056/NEJMc2206711. Epub ahead of print.

193. Naoum C, Hartmann M. Herpes zoster reactivation after COVID-19 vaccination - a retrospective case series of 22 patients. Int J Dermatol. 2022 May;61(5):628-629.

194. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021 Sep 16;385(12):1078-1090.

195. Birabaharan M, Kaelber DC, Karris MY. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: A cohort study. J Am Acad Dermatol. 2022 Sep;87(3):649-651. doi: 10.1016/j.jaad.2021.11.025. Epub 2021 Nov 23. PMID: 34826538; PMCID: PMC8608757.

196. Wu Y, Kang L, Guo Z, Liu J, Liu M and Liang W. Incubation
period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic
review and meta-analysis. JAMA Netw Open. 2022;5(8):e2228008.

197. Ständige Impfkommission: Beschluss der STIKO zur 21. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2022;33:3-19

198. https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu

199. Gray S et a l. NEJM online, 14. September 2022

200. Qu P, Faraone JN, Evans JP, Zheng YM, Yu L, Ma Q, Carlin C, Lozanski G, Saif LJ, Oltz EM, Gumina RJ, Liu SL. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2210546.

201. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, Meltzer L, Asraf K, Cohen C, Fluss R, Biber A, Nemet I, Kliker L, Joseph G, Doolman R, Mendelson E, Freedman LS, Harats D, Kreiss Y, Lustig Y. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. N Engl J Med. 2022 Apr 7;386(14):1377-1380.

202. Ständige Impfkommission: Beschluss der STIKO zur 22. Aktualisierung der COVID-19-Impfempfehlung Epid Bull 2022;40:3-20.

203. Piechotta V, Vygen-Bonnet S, Koch J, Berner R, Bogdan C, Burchard G, Garbe E, Heininger U, Hummers E, von Kries R, Ledig T, Littmann M, Meerpohl J, Mertens T, Meyer H, Röbl-Mathieu M, van der Sande M, Sander L E, Schmid-Küpke, Terhardt M, Überla K, Wichmann O, Wicker S, Wiedermann-Schmidt U, Widders G, Zepp F: Wissenschaftliche Begründung der STIKO zur Auf­frischimpfung von Personen ≥12 Jahren mit einem Omikron-BA.1- oder einem Omikron-BA.4/5-adaptierten bivalenten mRNA-Impfstoff Epid Bull 2022;40:21-34.

204. https://www.ecdc.europa.eu/en/publications-data/spread-sars-cov-2-omicron-variant-sub-lineage-bq1-eueea

205. Ständige Impfkommission: Beschluss der STIKO zur 23. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2022;46:3-21

206. Koch J, Piechotta V, Vygen-Bonnet S, Armann J, Berner R, Bogdan C, Burchard G, Garbe E, Heininger U, Hummers E, von Kries R, Ledig T, Littmann M, Meerpohl J, Mertens T, Meyer H, , Röbl-Mathieu M, Neufeind J, van der Sande M, Schlaberg J, Schmid-Küpke N, Siemens W, Terhardt M, Thielemann I, Überla K, Wichmann O, Wicker S, Wiedermann-Schmidt U, Widders G, Wild V, Zepp F: Wissenschaft­liche Begründung der STIKO für die COVID-19-Impfempfehlung für Kinder im Alter von 6 Monaten bis 4 Jahren sowie zur Anpassung der COVID-19-Impfempfehlung für Kinder im Alter von 5 – 11 Jahren. Epid Bull 2022;46:22-47

207. Chalkias, S., Eder, F., Essink, B. et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med 28, 2388–2397 (2022).

208. https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/COVID-19/Impfempfehlung-Zusfassung.html

209. https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-treiben-strategie-fuer-covid-19-impfstoffe

210. https://s29.q4cdn.com/435878511/files/doc_news/Modernas-BA.4BA.5-Targeting-Bivalent-Booster-mRNA-1273.222-Meets-Primary-Endpoint-of-Superiority-Against-Omicron-Variants-Compared-to-0ILWR.pdf

211. https://www.biorxiv.org/content/10.1101/2022.11.17.516898v1

212. Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines. N Engl J Med. 2022 Dec 15;387(24):2203-2206

213. Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, Hober S, Gordon M, Blom K, Klingström J, Åberg M, Smed-Sörensen A, Thålin C. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. N Engl J Med. 2022 Oct 6;387(14):1333-1336.

214. Herrera-Comoglio R, Lane S. Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine. N Engl J Med 2022; 387:1431-1432

215. Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. N Engl J Med. 2022 Dec 1;387(22):2092-2094.

216. New York Times, 7. Januar 2023. https://www.nytimes.com/2023/01/07/science/covid-omicron-variants-xbb.html

217. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, Porter-Morrison A, Hentenaar IT, Yamamoto F, Godbole S, Liu Y, Douek DC, Lee FE, Rouphael N, Moreno A, Pinsky BA, Suthar MS. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022 Dec 21:NEJMc2214293. doi: 10.1056/NEJMc2214293. Epub ahead of print.

218. Abara WE, Gee J, Marquez P, Woo J, Myers TR, DeSantis A, Baumblatt JAG, Woo EJ, Thompson D, Nair N, Su JR, Shimabukuro TT, Shay DK. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. JAMA Netw Open. 2023 Feb 1;6(2):e2253845. doi: 10.1001/jamanetworkopen.2022.53845. PMID: 36723942; PMCID: PMC9892957.

219. RKI - Empfehlungen der STIKO - Stellungnahme der STIKO zur COVID-19-Impfung in der Schwangerschaft

220. Ständige Impfkommission: Beschluss der STIKO zur 25. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2023;8:3-21

221. RKI - Empfehlungen der STIKO - Pressemitteilung der STIKO: Aufnahme der COVID-19-Impfung in die allgemeinen STIKO-Impfempfehlungen 2023

222. Gao P, Liu J, Liu M. Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022 Sep 29;19(19):12422. doi: 10.3390/ijerph191912422.

223. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z, Issa H, Cheng B, Abu Raddad LJ, Buckeridge DL, Van Kerkhove MD, Piechotta V, Higdon MM, Wilder-Smith A, Bergeri I, Feikin DR, Arora RK, Patel MK, Subissi L. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023 May;23(5):556-567.

224. Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 Mar 1;6(3):e232598. doi: 10.1001/jamanetworkopen.2023.2598.

225. Lipschuetz M, Guedalia J, Cohen SM, Sompolinsky Y, Shefer G, Melul E, Ergaz-Shaltiel Z, Goldman-Wohl D, Yagel S, Calderon-Margalit R, Beharier O. Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization. Nat Med. 2023 Mar 23. doi: 10.1038/s41591-023-02270-2. Epub ahead of print.

226. STIKO. Implementierung der COVID-19- Impfung in die allgemeinen Empfehlungen der STIKO 2023. Epid Bull 2023;21:3-6

227. Koch J, Piechotta V, Berner R, Bogdan C, Burchard G, Heininger U, Hummers E, von Kries R, Ledig T, Littmann M, Meerpohl J, Mertens T, Röbl-Mathieu M, van der Sande M, Sander L E, Terhardt M, Überla K, Vygen-Bonnet S, Wichmann O, Wicker S, Wiedermann-Schmidt U, Widders G, Zepp F: Empfehlung der STIKO zur Implementierung der COVID-19-Impfung in die Empfehlungen der STIKO 2023 und die dazugehörige wissenschaftliche Begründung Epid Bull 2023;21:7-48.

228. Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, Lockhart S, Riesenberg R, Sexter JM, Czajka H, Paulsen GC, Maldonado Y, Walter EB, Talaat KR, Englund JA, Sarwar UN, Hansen C, Iwamoto M, Webber C, Cunliffe L, Ukkonen B, Martínez SN, Pahud BA, Munjal I, Domachowske JB, Swanson KA, Ma H, Koury K, Mather S, Lu C, Zou J, Xie X, Shi PY, Cooper D, Türeci Ö, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. N Engl J Med. 2023 Feb 16;388(7):621-634.

229. Lipschuetz M, Guedalia J, Cohen SM, Sompolinsky Y, Shefer G, Melul E, Ergaz-Shaltiel Z, Goldman-Wohl D, Yagel S, Calderon-Margalit R, Beharier O. Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization. Nat Med. 2023 May;29(5):1155-1163.

230. Moulia DL, Wallace M, Roper LE, et al. Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months - United States, April 2023. MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):657-662.

231. Muñoz FM, Sher LD, Sabharwal C, et al. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. N Engl J Med. 2023 Feb 16;388(7):621-634.

232. Fleming-Dutra KE, Ciesla AA, Roper LE, et al. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023 Feb 17;72(7):177-182.

233. http://www.promedmail.org PRO/AH/EDR> COVID-19 update (30): omicron EG.5.1, updates, WHO, global (Mitteilung vom 15. August 2023)

234. https://www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.pdf?sfvrsn=2aa2daee_1 (Zugegriffen am 15. August 2023)

235. 2023-31.pdf (rki.de)